Genzyme Named to Dow Jones Sustainability World and North American Indexes

Ranks in Top 10 Percent of Healthcare Sector for Economic, Environmental and Social Sustainability

Genzyme Corporation (Nasdaq: GENZ) announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.

Genzyme is one of only three biotechnology companies in the United States to be named to the Dow Jones Sustainability World Index this year. More than 2,500 companies apply to be named to the Dow Jones Sustainability World Index and only 300 companies are selected. According to the survey, Genzyme scored the highest in the World Index for its employee code of conduct. Genzyme also scored particularly well in the following areas: corporate governance, environmental policy and talent acquisition and retention.

“Genzyme’s commitment to sustainable long-term growth and social responsibility is integral to our way of doing business,” said Henri Termeer, CEO of Genzyme. “We are focused first and foremost on patients with unmet medical needs and we work to help developing countries build sustainable healthcare systems while providing access to free drug programs, humanitarian initiatives, education and advocacy. From the design of our facilities to how we run our business, Genzyme is reducing our environmental impact and is engaged in supporting our communities.”

As part of its commitment to meeting unmet medical needs, Genzyme supports efforts to discover and advance novel treatments for neglected diseases such as malaria, sleeping sickness and Chagas Disease through its Humanitarian Assistance for Neglected Diseases (HAND) initiative. Genzyme and its partner organizations were recognized for the HAND program at the Clinton Global Initiative.

Genzyme’s commitment also extends to the environment and the communities in which it operates. Genzyme’s headquarters is one of the most environmentally responsible office buildings in the United States, and it is a leader in waste-reduction and recycling efforts at its sites around the world. Last year, Genzyme donated more than $15.5 million to local nonprofit organizations in its communities.

Corporate Sustainability is a business approach through which companies create long-term shareholder value by embracing opportunities and managing risks related to economic, environmental and social developments. This annual review is based on a thorough analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, branding, climate change mitigation, supply chain standards and labor practices. It accounts for general as well as industry specific sustainability criteria for each of 58 sectors defined according to the Industry Classification Benchmark (ICB).

In addition to being named to the Dow Jones Indexes, Genzyme was named to CRO Magazine’s “100 Best Corporate Citizens List 2009” which selects companies based on their performance in seven categories: environment, climate change, human rights, philanthropy, employee relations, finance and governance. Genzyme was also recognized in 2009 as one of the “Global 100 Most Sustainable Corporations in World” by Innovest Strategic Value Advisors for the third consecutive year and received the 2008 Scrip Award for Corporate Social Responsibility for its collaboration with the Oswaldo Cruz Foundation (Fiocruz).

To learn more about this year’s Dow Jones Sustainability World Index and North American index please visit: www.sustainability-index.com. To learn more about Genzyme’s CSR programs www.genzyme.com/commitment/commitment_home.asp.

About Genzyme

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

About SAM

SAM is an investment boutique focused exclusively on Sustainability Investing. The firm’s offering comprises asset management, indexes and private equity. Its asset management capabilities include a range of single-theme, multitheme and core sustainability investment strategies catering to institutional asset owners and financial intermediaries in Europe, the United States, Asia-Pacific and the Middle East. Through its index activities, SAM has partnered with Dow Jones Indexes and STOXX Limited for the publication and licensing of the globally recognized Dow Jones Sustainability Indexes (DJSI) as well as customized sustainability benchmarks. Furthermore, SAM is the center of expertise for clean tech private equity within Robeco. Based on its Corporate Sustainability Assessment, SAM has compiled one of the world’s largest sustainability databases and analyzes over 1,000 listed companies annually. SAM’s proprietary research and sustainability data are fully integrated into its offering.

SAM is a member of Robeco, which was established in 1929 and offers a broad range of investment products and services worldwide. Robeco is a subsidiary of the AAA-rated Rabobank Group.SAM was founded in 1995, is headquartered in Zurich and employs over 100 professionals. As of 30th June 2009, SAM’s total assets amount to USD 11.6 billion.

About Dow Jones Indexes

A full-service index provider, Dow Jones Indexes develops, maintains and licenses indexes for use as benchmarks and as the basis of investment products. Best known for the Dow Jones Industrial Average, Dow Jones Indexes also is coowner of the Dow Jones STOXX indexes, the world’s leading pan-European indexes that are an integrated segment of the Dow Jones Global Index series. Additionally, Dow Jones Indexes maintains its benchmark index series, the Dow

Jones Total Stock Market Indexes, which is anchored by the Dow Jones U.S. Total Stock Market Index and covers more than 12,000 securities in 65 markets. Beyond equity indexes, Dow Jones Indexes maintains a number of alternative indexes, including measures of the hedge fund and commodity markets. Dow Jones indexes are maintained according to clear, unbiased and systematic methodologies that are fully integrated within index families. www.djindexes.com

Dow Jones & Company (www.dowjones.com) is a News Corporation company (NASDAQ: NWS, NWSA; ASX: NWS, NWSLV; www.newscorp.com). Dow Jones is a leading provider of global business news and information services. Its Consumer Media Group publishes The Wall Street Journal, Barron’s, MarketWatch and the Far Eastern Economic Review. Its Enterprise Media Group includes Dow Jones Newswires, Dow Jones Factiva, Dow Jones Client Solutions,

Dow Jones Indexes and Dow Jones Financial Information Services. Its Local Media Group operates community-based information franchises. Dow Jones owns 50% of SmartMoney and 33% of STOXX Ltd. and provides news content to radio stations in the U.S.

Genzyme’s press releases and other company information are available at www.genzyme.com and by calling Genzyme’s investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.